Skip to main content

Advertisement

SpringerLink
Log in

Palliative Care and End-of-Life Decisions in Interstitial Lung Disease

  • REVIEW
  • Published:
Current Pulmonology Reports Aims and scope Submit manuscript

A Correction to this article was published on 31 May 2023

This article has been updated

Abstract

Purpose of Review

This review examines recent pulmonary and palliative medicine literature to evaluate the current state of palliative and end-of-life care in interstitial lung diseases (ILDs), addressing unmet needs, challenges, and evidence for best practices.

Recent Findings

Patients with ILD and their caregivers do not receive timely and comprehensive supportive and palliative care due to barriers in initiating palliative care on the part of healthcare teams as well as patients and caregivers. Multidisciplinary teams with early integrated palliative care can offer better palliative care for patients with ILD and caregivers, facilitating better advance care planning, improved symptom control, and health-related quality of life.

Summary

ILDs are associated with a high symptom burden for patients and a negative health impact on caregivers as well. Adoption of simple prognostication tools in clinical practice, additional training in essentials of palliative care, effective and safe non-pharmacological and pharmacological means of alleviating common symptoms, multidisciplinary care models, and telehealth are promising ways to address the gap between guidelines and implementation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

References

Papers of particular interest, published recently, have been highlighted as:

    • Of importance

      •• Of major importance

      1. Johannson et al. Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet 2021;398:1450–60.

      2. Goos et al. Defining and predicting progression in non-IPF interstitial lung disease. Res Med. 2021;189:106626.

      3. • Kreuter et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017;5: 968–80. This comprehensive review offers a model of living well with ILD, the ABCDE of interstitial lung disease care which advocates on a disease behaviour-based approach, which includes pharmacological as well as non-phramacological modalities for symptom management and improving health-related quality of life of patients with ILD.

      4. Lindell et al. The palliative care needs of patients with idiopathic pulmonary fibrosis: a qualitative study of patients and family caregivers. Heart Lung. 2017;46(1): 24–29

      5. Leng et al. Respiratory problems in low resource settings. Curr Opin Support Palliat Care. 2017;11:000–000.

      6. Raghu et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.

      7. Marsaa et al. Danish respiratory society position paper: palliative care in patients with chronic progressive non-malignant lung diseases. Eur Clin Res J. 2018;5:1530029.

      8. Singh S, Sharma BB, Bairwa M, Gothi D, Desai U, Joshi JM, et al. Management of interstitial lung diseases: a consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India. 2020;37:359–78.

        Article  PubMed  PubMed Central  Google Scholar 

      9. Reipas et al. Examining the characteristics of patients with non-malignant lung disease at the time of referral to an inter-professional supportive care clinic. Am J Hosp Palliat Care®. 2021;38(11):1329–1335.

      10. Koyauchi et al. Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study. Thorax. 2021;76:248–255.

      11. Smallwood et al. Patients with fibrotic interstitial lung disease receive supportive and palliative care just prior to death. Am J Hosp Palliat Care®. 2021;38(2):154–160.

      12. Philip et al. Referral criteria to palliative care for patients with respiratory disease: a systematic review. Eur Res J. 2021.

      13. Sorensen et al. Attitude and barriers in palliative care and advance care planning in nonmalignant chronic lung disease: results from a Danish national survey. J Palliat Care. 2020;35(4):232–235.

      14. Tikellis et al. Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia. Respirology. 2022;27:76–84.

      15. Akiyama et al. Palliative care for idiopathic pulmonary fibrosis patients: pulmonary physicians’ view. J Pain Symptom Manag. 2020;60:933e940.

      16. Gersten et al. Provider perspectives on and access to palliative care for patients with interstitial lung disease. Chest. 2022.

      17. Kim JW et al. Interstitial lung disease and specialist palliative care access: a healthcare professionals survey. BMJ Support Palliat Care. 2020.

      18. Trandel et al. Palliative care skills in CF: perspectives of adults with CF, caregivers, and CF care team members. Pediatr Pulmonol. 2020;55(8):2017–2024.

      19. Cassidy et al. Fibrotic interstitial lung disease - palliative care needs: a World-Café qualitative study. BMJ Support Palliat Care. 2021;0:1–8.

      20. Kalluri et al. What patients with idiopathic pulmonary fibrosis and caregivers want: filling the gaps with patient reported outcomes and experience measures. Am J Med. 2020;133:281−289.

      21. Hui and Bruera. The Edmonton symptom assessment system 25 years later: past, present and future developments. J Pain Symptom Manage. 2017;53(3):630–43.

        Article  PubMed  Google Scholar 

      22. Gersten RA, Moale AC, Seth B, et al. A scoping review of palliative care outcome measures in interstitial lung disease. Eur Respir Rev. 2021;30:210080.

      23. Wong et al. Providing patient-centered care in interstitial lung disease. Clin Chest Med. 2021;42:337–346.

      24. Pan et al. Management of respiratory symptoms in those with serious illness. Med Clin N Am. 2020;104:455–470.

      25. Carvajalino S, et al. Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review. BMC Pulm Med. 2018;18.1:1–11.

      26. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31(1):58–69.

        Article  Google Scholar 

      27. Spathis et al. The breathing, thinking, functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. Primary Care Res Med. 2017;27.

      28. Johnson et al. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. Eur Respir J. 2017;49(5):1602277.

      29. Shah RJ, et al. Care of people with pulmonary disorders, burden, resilience and coping in caregivers of patients with interstitial lung disease. Heart Lung. 2018;47:264–8.

        Article  CAS  PubMed  PubMed Central  Google Scholar 

      30. Kahlmann et al. Managing fatigue in patients with interstitial lung disease. Chest. 2020;158(5):2026–203.

      31. Ascher et al. Management of insomnia in chronic lung disease. Curr Pulmonol Rep. 2020;9:102–109.

      32. Glaspole IN, Watson AL, Allan H, et al. Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. Eur Respir J. 2017;50:1700168.

      33. Higginson et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir Med. 2014;2: 979–87.

      34. Jacobs et al. Home oxygen therapy for adults with chronic lung disease an official american thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;202(10):e121–e141.

      35. Brunetti et al. Pulmonary rehabilitation in patients with interstitial lung diseases: correlates of success. Res Med. 2021;185:106473.

      36. Birring et al. Treatment of interstitial lung disease-associated cough, CHEST guideline and expert panel report. Chest. 2018;154(4):904–917.

      37. Bausewein et al. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev. 2013;2013(11):CD005623.

      38. Kronborg-White et al. Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease – a randomised placebo-controlled trial. Respir Res. 2020;21:195.

      39. Fong et al. Buccal hydromorphone syrup for managing dyspnea in idiopathic pulmonary fibrosis. Am J Hosp Palliat Care®. 2021;38(8):1046–1052.

      40. Pisani et al. Management of dyspnea in the terminally Ill. Chest. 2018;154(4):925–934.

      41. Bajwah et al. Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study. Eur Respir J. 2018;52:1801278.

      42. Ambrosino et al. Strategies to relieve dyspnoea in patients with advanced chronic respiratory diseases. A narrative review. Pulmonol. 2019;25(5):289–298.

      43. Glassberg MK, Wijsenbeek MS, Gilberg F, et al. Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019;54:1900399.

        Article  PubMed  PubMed Central  Google Scholar 

      44. Chen C-H et al. The safety of nintedanib for the treatment of interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2021;16(5):e0251636.

      45. Harari et al. Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study. Respiration. 2022;101:577–584.

      46. Van Manen MJG, Birring SS, Vancheri C, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017;50:1701157.

        Article  PubMed  PubMed Central  Google Scholar 

      47. Volkmann et al. Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of scleroderma lung study II. Open Rheumatol J. 2020;2(6):362–370.

      48. Higginson et al. Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease, (BETTER-B feasibility). Thorax 2020;75:176–179.

      49. Rosenberg. The relationship of SSRI and SNRI usage with interstitial lung disease and bronchiectasis in an elderly population: a case–control study. Clin Interv Aging. 2017.

      50. Jabbarian LJ, et al. Advance care planning for patients with chronic respiratory diseases: a systematic review of preferences and practices. Thorax. 2018;73:222–30.

        Article  PubMed  Google Scholar 

      51. •• Moor et al. The value of the surprise question to predict one-year mortality in idiopathic pulmonary fibrosis: a prospective cohort study. Respiration. 2021;100:780–785. The difficulty in prognostication of ILD patients has been quoted as a barrier to timely initiation of advance care planning in patients. This single centre study of 140 patients with ILD showed that the Surprise Question- ‘Would you be surprised if this patient were to die within 1 year?’ is a useful tool to guide initiation of advance care planning. More patients with ILD may be referred for timely palliative care with adoption of this simple tool.

      52. Huapaya JA, et al. Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit. Eur Respir Rev. 2018;27:180061.

        Article  PubMed  PubMed Central  Google Scholar 

      53. Palmer et al. Which factors influence the quality of end-of-life care in interstitial lung disease? A systematic review with narrative synthesis. Palliative Med. 2022;36(2):237–253.

      54. Guo et al. Investigation burden for patients with fibrotic interstitial lung disease at the end of life. Intern Med J 2020;50:748–752.

      55. Tsen C, et al. Impact of palliative care in end-of-life of fibrotic interstitial lung disease patients. Am J Hosp Palliat Care®. 2022;0(0):1–9.

      56. Kalluri et al. Advance care planning needs in idiopathic pulmonary fibrosis: a qualitative study. Am J Hosp Palliat Care®. 2021;1–11.

      57. Sprung et al. The consensus for Worldwide End-of-Life Practice for Patients in Intensive Care Units (WELPICUS) study. Am J Respir Crit Care Med. 2014;190(8):855–866.

      58. Koyauchi et al. Impact of end‑of‑life respiratory modalities on quality of dying and death and symptom relief in patients with interstitial lung disease: a multicenter descriptive cross‑sectional study. Respir Res. 2022;23:79.

      59. Egerod I, et al. Spousal bereavement after fibrotic interstitial lung disease: a qualitative study. Respir Med. 2019;146:129–36.

        Article  PubMed  Google Scholar 

      60. Thorns A. Ethical and legal issues in end-of-life care. Clin Med. 2010;10(3):282–5.

        Article  Google Scholar 

      61. Archibald et al. Early integrated palliative care bundle impacts location of death in interstitial lung disease: a pilot retrospective study. Am J Hosp Palliat Care®. 2021;38(2):104–113.

      62. Nolley et al. The role of palliative care in lung transplantation. J Thorac Dis. 2021;13(11):6737–6746.

      63. • Bischoff et al. Better together: a mixed-methods study of palliative care co-management for patients with interstitial lung disease. J Palliat Med. 2021;24. This small mixed-methods pilot study of palliative co-management of patients with moderately severe ILD , using telehealth when needed, shows the possible ways of expanding access to advance care planning and timely opioids for symptom relief. There are useful insights in the qualitative arm of the study in the thematic analysis of interviews with patients and caregivers as well as clinician focus groups that can inform adaptation of similar models to different practice contexts and geographies.

      64. Barratt SL, Morales M, Speirs T, et al. Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs. BMJ Open Resp Res. 2018;5:e000360.

        Article  PubMed  PubMed Central  Google Scholar 

      65. Sinclair C, Auret KA, Evans SF, et al. Advance care planning uptake among patients with severe lung disease: a randomised patient preference trial of a nurse-led, facilitated advance care planning intervention. BMJ Open. 2017;7: e013415.

        Article  PubMed  PubMed Central  Google Scholar 

      66. Lindell K. Veatch et al. Nurse-led palliative care clinical trial improves knowledge and preparedness in caregivers of patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2021;18(11):1811–21.

        Article  PubMed  PubMed Central  Google Scholar 

      67. Schunk et al. BreathEase: rationale, design and recruitment of a randomised trial and embedded mixed-methods study of a multiprofessional breathlessness service in early palliative care. ERJ Open Res. 2021;7:00228–2020.

      68. Aronson et al. Patient-centered outcomes research in interstitial lung disease- an official American Thoracic Society research statement. Am J Respir Care Med. 2021;204:616.

      Download references

      Author information

      Authors and Affiliations

      1. Department of Pulmonology, Sparsh Hospitals, Bangalore, Mysore Road, Bangalore, Karnataka, 560098, India

        Rajani Surendar Bhat & Sunitha Daniel

      Authors
      1. Rajani Surendar Bhat
        View author publications

        You can also search for this author in PubMed Google Scholar

      2. Sunitha Daniel
        View author publications

        You can also search for this author in PubMed Google Scholar

      Corresponding author

      Correspondence to Rajani Surendar Bhat.

      Ethics declarations

      Conflict of Interest

      The authors declare no competing interests.

      Human and Animal Rights and Informed Consent

      This article does not contain any studies with human or animal subjects performed by any of the authors.

      Additional information

      Publisher's Note

      Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

      Rights and permissions

      Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

      Reprints and permissions

      About this article

      Check for updates. Verify currency and authenticity via CrossMark

      Cite this article

      Bhat, R.S., Daniel, S. Palliative Care and End-of-Life Decisions in Interstitial Lung Disease. Curr Pulmonol Rep 12, 80–88 (2023). https://doi.org/10.1007/s13665-023-00306-z

      Download citation

      • Accepted:

      • Published:

      • Issue Date:

      • DOI: https://doi.org/10.1007/s13665-023-00306-z

      Keywords

      Search

      Navigation